Galectin-3+PD-L1+ CECs identified as immunosuppressive drivers in TNBC
The study identifies Galectin-3+PD-L1+ CD71+ erythroid cells as key immunosuppressive components in triple-negative breast cancer.
Phase III
triple-negative breast cancer (TNBC)
Status
Negative
Sponsor
PD-L1
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The identification of Galectin-3+PD-L1+ CD71+ erythroid cells as immunosuppressive drivers in TNBC presents a significant opportunity for pharmaceutical companies to refine their immunotherapy strategies. This finding could lead to the development of novel therapeutic targets that enhance the efficacy of existing treatments, particularly those involving PD-L1 blockade.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor developments in therapies targeting Gal-3 and PD-L1 interactions, as well as clinical trials focusing on CECs in TNBC.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.